Management Team

Our management team has an extremely long track record of working successfully together in developing pharmaceuticals, biotechnology drugs and medical devices.

​Medivation’s executive team boasts experts from many facets of the healthcare industry, all of whom have a proven track record in medical product development. As seasoned business people and as clinicians and scientists, they guide Medivation in the acquisition and development of our technologies, bringing them from the laboratory bench to the patient bedside quickly, efficiently and with enhanced value.

David Hung, M.D.
David Hung, M.D.
President and Chief Executive Officer, Director
Dr. Hung is a co-founder of Medivation and served as president, chief executive officer and director of Medivation Neurology since its inception in September 2003. He became president and chief executive officer of Medivation, Inc. and a member of the Board of Directors when the Company acquired its subsidiary Medivation Neurology, Inc. in December 2004. From 1998 to 2001, Dr. Hung served as chief scientific officer (1998-1999) and as president, chief executive officer and director (1999-2001) of Pro-Duct Health, Inc., a privately-held medical device company focused on breast cancer cytological diagnostics. Pro-Duct Health, Inc. was acquired in 2001 by Cytyc Corporation for $167 million after having spent only approximately $22 million in total development costs. From 1996 to 1998, Dr. Hung served in various senior positions at Chiron Corporation, most recently as vice president of lead discovery and development and vice president of new projects. Dr. Hung received an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine, and an A.B. summa cum laude in biology from Harvard College.

Rick Bierly
Rick Bierly
Chief Financial Officer
Rick Bierly was appointed chief financial officer in March 2014. Previously he served as an executive director in Ernst & Young’s (EY) Financial Accounting Advisory Services practice for life sciences and other clients. From 1999 to 2012, he served in several leadership roles at Johnson & Johnson, including vice president, Skillman NJ Shared Financial Services Center, where he was responsible for a shared services center providing financial accounting services to Johnson and Johnson’s US-based operating companies. He also served as vice president and chief financial officer of Centocor and Ortho Biotech, and prior to that served as executive director, finance, following the acquisition of the Centocor biotechnology business by Johnson and Johnson. From 1997 to 1999 he was at Centocor Diagnostics as vice president and chief financial officer and Centocor as executive director, finance. From 1995 to 1997 he served as vice president and treasurer of a Aventis-Hoechst start-up joint venture in the blood plasma business. He also worked in senior financial roles at Aventis (1991 to 1995) and SmithKline Beecham (1981 to 1991). He began his career in public accounting at EY. He holds a Bachelor of Business Administration degree from Pennsylvania State University and is a CPA in PA and NJ (inactive).

Sandy Cooper
Sandy Cooper
Senior Vice President, Human Resources
Sandy Cooper was named senior vice president in March of 2015, having joined the company as vice president of human resources in April 2012. Previously she served as the vice president of human resources for the U.S. affiliate of the French pharmaceutical company Ipsen. While there she led the post-acquisition integration of Tercica, including the relocation of the U.S. headquarters from South San Francisco to New Jersey. From 2003 until 2009 she served as the first senior vice president of human resources for Dey L.P. (Merck KGaA). As a member of the Senior Executive Committee, she repositioned the Human Resources function to support 24/7 manufacturing and development organization of 1,500 employees. The Merck KGaA subsidiary was sold to Mylan in 2008. Ms. Cooper’s previous roles have also included vice president of human resources for Elan Pharmaceuticals (3,700 employees) where her responsibilities included leading the integration of several acquisitions, and providing Human Resources leadership for their U.S. and portions of their global organization. She also served as vice president of operations for Cacheon, a Pre-IPO B2B software company, and senior director of human resources for the global medical device company, Nellcor Puritan Bennett, which was acquired by Mallinckrodt. She holds a Master of Arts in Business Administration from Webster University.

Mohammad Hirmand, M.D.
Mohammad Hirmand, M.D.
Interim Chief Medical Officer
Dr. Hirmand was appointed interim chief medical officer in October 2015. From 2007 to 2014 he served as senior director, clinical development and most recently served as senior vice president of clinical development and operations at Medivation. Before joining Medivation, he was a senior director of clinical development at Nuvelo, Inc. (now ARCA biopharma), where he led the clinical development department comprised of clinical operations, clinical data management and clinical sciences/medical monitor staff. Before that, he served as director of oncology development at SuperGen, Inc. (now Astex Pharmaceuticals, Inc) and as associate director of clinical research at Amgen, Inc. (formerly Tularik, Inc.), where he led clinical development efforts for Tularik's oncology trials. Early in his career, he was a clinical scientist and manager of market development and product evaluation at Theravance Biopharma, Inc. Dr. Hirmand holds a Bachelor of Arts degree from Cornell University. Dr. Hirmand received his M.D. from Harvard Medical School.

Joseph Lobacki
Joseph Lobacki
Chief Commercial Officer
Mr. Lobacki was appointed chief commercial officer in December 2014. Previously, Mr. Lobacki served as the general manager of the oncology business at Idera Pharmaceuticals, senior vice president and chief commercial officer at Micromet Inc., senior vice president and general manager of transplant and oncology at Genzyme Corporation, vice president of North American marketing at SangStat Medical Corporation and vice president of operations of Cell Pathways, Inc. Mr. Lobacki currently serves on the Board of Directors for Celator Pharmaceuticals. Mr. Lobacki holds a Bachelor of Science degree in Biology from Boston College and a Bachelor of Science degree in Pharmacy from Massachusetts College of Pharmacy.

Marion McCourt
Marion McCourt
Chief Operating Officer
Ms. McCourt joined Medivation as chief operating officer in February 2016. She has more than two decades of wide-ranging executive management leadership experience at some of the world's most innovative biopharmaceutical companies. Previously she served as a vice president in U.S. commercial operations for Amgen Inc., one of the world's leading independent biotechnology companies, where she was part of the team that drove the Launch Readiness for multiple assets and led the Organized Customer Team. She also served as the vice president/general manager of the Bone Health & Primary Care Business Unit. Previously, she was the chief operating officer for AstraZeneca U.S. with leadership and P & L accountability for AstraZeneca's largest market with $13 billion in sales. Her responsibilities included oversight and direct report of all U.S. commercial functions, including medical affairs, business development, finance, human resources, legal, operations, payer-government and sales and marketing. During her 12-year tenure at AstraZeneca, Ms. McCourt was President & CEO of AstraZeneca Canada Inc. and also held the following roles in AstraZeneca Pharmaceuticals LP: Vice President US Business Development, Strategy & Launch; Vice President of Business Units; and Vice President Managed Markets, Government & Policy. She holds a B.S. degree in Biology from Lafayette College.

Andrew Powell
Andrew Powell
General Counsel and Corporate Secretary
Mr. Powell joined Medivation as senior vice president, general counsel and corporate secretary in May 2015. He brings to Medivation more than 25 years of leadership experience in the life sciences, most recently as executive vice president, general counsel and corporate secretary of InterMune, where he helped the company prepare for the U.S. approval and launch of Esbriet® (pirfenidone) as a treatment for idiopathic pulmonary fibrosis and played a leadership role in InterMune’s acquisition by Swiss drug maker Roche for more than $8 billion. Early in his career, Mr. Powell held positions of increasing responsibility for nearly 15 years at the multi-national healthcare company Baxter, where he was instrumental in a series of transactions that established Baxter throughout Asia; Mr. Powell led the global law practice at Baxter Bioscience. Subsequently, he was part of the senior team that repositioned Collagenex Pharmaceuticals as a leader in dermatology. Mr. Powell then served as senior vice president and general counsel at ImClone Systems, where he helped the company grow before playing a key role in a successful process that resulted in a sale to Eli Lilly. Immediately prior to joining InterMune, he was executive vice president, general counsel and secretary at Cornerstone Therapeutics through its successful sale to Chiesi Farmaceutici S.p.A.

Top